Antibodies

16 Nov 2016 Tiziana Life Sciences Announces New Data with Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases
16 Nov 2016 Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin
16 Nov 2016 Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting
16 Nov 2016 Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation in an Alzheimer’s mouse model
16 Nov 2016 Janssen Next-Generation Biologic Guselkumab Shows Promise In The Treatment Of Psoriatic Arthritis In Phase 2 Trial
16 Nov 2016 Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration
15 Nov 2016 AbbVie's HUMIRA® (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
15 Nov 2016 New Phase 3 Data Show Simponi Aria® (Golimumab) Significantly Improved Signs And Symptoms In Patients With Active Ankylosing Spondylitis
15 Nov 2016 Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2016 Annual Meeting
14 Nov 2016 Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody
14 Nov 2016 Oncobiologics Announces Presentation of Final Data from Phase 1 Clinical Study of ONS-3010 (HUMIRA® Biosimilar)
14 Nov 2016 Merck KGaA, Darmstadt, Germany's Phase IIb ADDRESS II Results Confirm Potential of Atacicept as a Candidate Therapy for SLE
14 Nov 2016 Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
14 Nov 2016 Results From Phase 3 BRIDGE Study Show Romosozumab Significantly Increases Bone Mineral Density In Men With Osteoporosis
14 Nov 2016 Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers
14 Nov 2016 Phase 1/2 Data Combining Urelumab with Opdivo (nivolumab) in Hematologic and Solid Tumors Suggest Increased Antitumor Effect in Patients with Melanoma
14 Nov 2016 Interim Phase 1/2 Data Show Encouraging Clinical Benefit for Lirilumab in Combination With Opdivo (nivolumab) in Patients With Advanced Platinum Refractory Squamous Cell Carcinoma of the Head and Neck
14 Nov 2016 Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Efficacy and Safety in Previously Treated Patients With Advanced Form of Bladder Cancer
14 Nov 2016 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer
14 Nov 2016 Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist
14 Nov 2016 Phase III GiACTA Study Shows Genentech’s Actemra® is Superior to Steroids Alone in Maintaining Steroid-Free Remission for People with Giant Cell Arteritis
14 Nov 2016 Celltrion Healthcare Showcases Data Supporting Efficacy and Safety of Both CT-P10 and CT-P13 Biosimilars
11 Nov 2016 Corvus Pharmaceuticals Announces Preliminary Phase 1/1b Clinical Data with Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety and Evidence of Anti-Tumor Activity as a Single Agent in Patients with Advanced Refractory Cancers
11 Nov 2016 Xencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and Additional Bispecific Antibody Candidates at Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
11 Nov 2016 BeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual Meeting

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top